Treatment for cerebral palsy gait impairment
AssigneeGilrose Pharmaceuticals, LLC
InventorsBruce Roseman, Gilla Kaplan
Life of this patent
Estimating the term…
Abstract
A methylphenidate, particularly including dextro-threo-methylphenidate, is administered to a child to treat a gait impairment and a speech impairment secondary to a non degenerative disease or disorder acquired in utero, at birth or in infancy, but later manifested.
Claims54
A pharmaceutical intervention for a gait or limb impairment secondary to a non degenerative disease or disorder acquired in utero, during birth or in infancy, in a subject in need of the intervention, wherein the limb or gait impairment is manifested later in the life of the subject, said pharmaceutical intervention comprises:
- a psychostimulant having mood-elevating or anti-depressant activity;
- whereby the gait or limb impairment is diminished.
A pharmaceutical intervention for treating a gait impairment secondary to cerebral palsy or other disease or disorder, said impairment being acquired in utero, at birth or in infancy but later manifested in a subject in need of such intervention, said pharmaceutical intervention comprises:
- a psychostimulant having mood-elevating or anti-depressant properties affecting neural pathway effecting gait;
- whereby the gait impairment is diminished.
A method for treating a gait or limb impairment secondary to a non degenerative disease or disorder acquired in utero, at birth or in infancy but later manifested in a subject in need of such treatment, said method comprises (a) administering a therapeutically effective dose of a psychostimulant having mood-elevating or anti-depressant activity effecting gait or limb neural pathways;
- whereby the gait or limb impairment is diminished.
A pharmaceutical intervention for treating a toe drop impairment secondary to a disease or disorder in a subject in need of such treatment, said pharmaceutical intervention comprises:
- a therapeutically effective dose of a psychostimulant, said psychostimulant having mood-elevating or anti-depressant activity;
- wherein the toe drop impairment is diminished.
The pharmaceutical intervention of claim 25, wherein there is greater heel-to-toe gait than toe-to-heel gait after the pharmaceutical intervention.
The pharmaceutical intervention of claim 25, wherein the subject is a child.
The pharmaceutical intervention of claim 25, wherein the subject has a speech impairment secondary to the disease or disorder and the speech impairment is diminished with the psychostimulant intervention.
The pharmaceutical intervention of claim 25, wherein the diminishment of the impairment persist when the psychostimulant is no longer efficaciously present.
The pharmaceutical intervention of claim 25, wherein the psychostimulant comprises a methylphenidate.
The pharmaceutical intervention of claim 25, wherein the impairment is genetic cerebral palsy.
A pharmaceutical intervention for treating a spasticity impairment secondary to cerebral palsy or other non-degeneratiave disease or disorder acquired in utero, at birth or in infancy, but later manifested in a subject in need of such intervention, said pharmaceutical intervention comprises:
- a psychostimulant having mood-elevating or anti-depressant properties;
- whereby the spasticity impairment is diminished.
A method for treating a spastic diplegia impairment resultant from an early in life acquired non-degenerative disease or disorder in a subject in need of such treatment, said method comprises;
- (a) administering a therapeutically effective dose of a psychostimulant having mood-elevating or anti-depressant activity;
- whereby the spastic diplegia impairment is diminished.
Dependencies are inferred from the claim text.